Merck Sharp + Dohme Corp.

Heather E Stevenson

Ian M Bell

Mark E Fraley

Daniel Vincent Paone

Cheng Wang

Helen J Mitchell

Steven N Gallicchio

Donnette D Staas

Anthony T Ginnetti

John M Sanders

John A McCauley

Thomas J Greshock

C Blair Zartman

Jonathan T Kern

Andrew William Stamford

Bernard R Neustadt

Mark T Bilodeau

Michael W Miller

Jack D Scott

Xing Dai

Duane E DeMong

Hong Liu

Marc Poirier

Hemaka Anthony Rajapakse

Joel M Harris

Kallol Basu

Vanessa L Rada

Boyoung Kim

Blair C Zartman

Daniel V Paone

John A Mccauley

Michael Miller

Anthony Ginnetti

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide indane CGRP receptor antagonists

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Compounds inhibiting leucine-rich repeat kinase enzyme activity

Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein 'A' is S&#x2014;; &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;O&#x2014; or NR&#x2014;, wherein Rac is H, or Calkyl and Rthrough Rare defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease. 

Leucine-rich repeat kinase enzyme activity

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide azaindane CGRP receptor antagonists

Growing community of inventors

Conshohocken, PA, United States of America

Heather E Stevenson